If you're seeking MS care in Connecticut, you have several established centers to consider across the state, including Hartford HealthCare Ayer Neuroscience Institute locations in Southington and others, The Mandell Center for Multiple Sclerosis (with a Waterbury site), and UConn Health’s Multiple Sclerosis Center. Use this guide to compare services, provider experience, and location so you can choose the center that best fits your needs and preferences.
8 MS treatment centers4 active clinical trialsTop centers: Hartford HealthCare Ayer, The Mandell Center, UConn Health12 providers with Medicare prescribing data
Center types in Connecticut
Dedicated MS Practice (4)
Boutique MS Practice (2)
Community Hospital Program (1)
Academic MS Center (1)
Filter by type:
50% of MS centers in Connecticut are classified as Dedicated MS Practice facilities.
Centers with Most Active Trials in Connecticut
Ranked by active clinical trial count from ClinicalTrials.gov. Not a quality ranking.
3. Hasbani Neurology1 trials
Largest Care Teams in Connecticut
1. Uconn Health Multiple Sclerosis Center6 providers
MS Care by City
Active MS clinical trials in Connecticut
See all 19 MS trials in Connecticut →ActivePhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Stamford
ActivePhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Fairfield
ActivePhase 3
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
Stamford
ActivePhase 3
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
Hoffmann-La Roche
North Haven
Active
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
Yale University
New Haven
ActivePhase 1
Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis
Griffin Hospital
Derby
RecruitingPhase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Hoffmann-La Roche
New Haven







